Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia

ClinicalTrials.gov ID: NCT00754221

Public ClinicalTrials.gov record NCT00754221. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Long-term, Open-label Extension Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study to investigate the long-term safety and effectiveness \[S,S\]-Reboxetine in relieving the symptoms of Fibromyalgia in patients.

Study identification

NCT ID
NCT00754221
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
390 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2008 (Type not available)
Primary completion
May 2009 (Actual)
Completion
May 2009 (Actual)
Last update posted
Dec 17, 2019

2008 – 2009

United States locations

U.S. sites
101
U.S. states
32
U.S. cities
90
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35242 —
Pfizer Investigational Site Phoenix Arizona 85023 —
Pfizer Investigational Site Tucson Arizona 85741 —
Pfizer Investigational Site Elk Grove California 95758 —
Pfizer Investigational Site Fullerton California 92835 —
Pfizer Investigational Site Lafayette California 94549 —
Pfizer Investigational Site Northridge California 91325 —
Pfizer Investigational Site Oceanside California 92056 —
Pfizer Investigational Site Roseville California 95661 —
Pfizer Investigational Site Sacramento California 95816 —
Pfizer Investigational Site San Jose California 95124 —
Pfizer Investigational Site Santa Ana California 92705 —
Pfizer Investigational Site New London Connecticut 06320 —
Pfizer Investigational Site Brooksville Florida 34613 —
Pfizer Investigational Site Jacksonville Florida 32216 —
Pfizer Investigational Site Jacksonville Florida 32223 —
Pfizer Investigational Site Ocala Florida 34471 —
Pfizer Investigational Site Ocala Florida 34474 —
Pfizer Investigational Site St. Petersburg Florida 33709 —
Pfizer Investigational Site Sunrise Florida 33351 —
Pfizer Investigational Site Tampa Florida 33606 —
Pfizer Investigational Site Tampa Florida 33614 —
Pfizer Investigational Site West Palm Beach Florida 33407 —
Pfizer Investigational Site Winter Haven Florida 33880 —
Pfizer Investigational Site Atlanta Georgia 30328 —
Pfizer Investigational Site Gurnee Illinois 60031 —
Pfizer Investigational Site Moline Illinois 61265 —
Pfizer Investigational Site Oak Brook Illinois 60523 —
Pfizer Investigational Site Indianapolis Indiana 46250 —
Pfizer Investigational Site Indianapolis Indiana 46260 —
Pfizer Investigational Site Overland Park Kansas 66212 —
Pfizer Investigational Site Overland Park Kansas 66215 —
Pfizer Investigational Site Pratt Kansas 67124 —
Pfizer Investigational Site Louisville Kentucky 40213 —
Pfizer Investigational Site Madisonville Kentucky 42431 —
Pfizer Investigational Site Mount Sterling Kentucky 40353 —
Pfizer Investigational Site Baton Rouge Louisiana 70809 —
Pfizer Investigational Site Wheaton Maryland 20902 —
Pfizer Investigational Site Boston Massachusetts 02135 —
Pfizer Investigational Site Brockton Massachusetts 02301 —
Pfizer Investigational Site Fall River Massachusetts 02720 —
Pfizer Investigational Site North Dartmouth Massachusetts 02747 —
Pfizer Investigational Site Watertown Massachusetts 02472 —
Pfizer Investigational Site Wellesley Hills Massachusetts 02481-2106 —
Pfizer Investigational Site Worcester Massachusetts 01610 —
Pfizer Investigational Site Ann Arbor Michigan 48103 —
Pfizer Investigational Site Chaska Minnesota 55318 —
Pfizer Investigational Site Edina Minnesota 55435 —
Pfizer Investigational Site Olive Branch Mississippi 38654 —
Pfizer Investigational Site Columbia Missouri 65203 —
Pfizer Investigational Site Columbia Missouri 65212 —
Pfizer Investigational Site Jefferson City Missouri 65109 —
Pfizer Investigational Site St Louis Missouri 63141 —
Pfizer Investigational Site Omaha Nebraska 68134 —
Pfizer Investigational Site Las Vegas Nevada 89119 —
Pfizer Investigational Site Albuquerque New Mexico 87109 —
Pfizer Investigational Site Albany New York 12205 —
Pfizer Investigational Site Brooklyn New York 11235 —
Pfizer Investigational Site Rochester New York 14610 —
Pfizer Investigational Site Rochester New York 14618 —
Pfizer Investigational Site The Bronx New York 10454 —
Pfizer Investigational Site Charlotte North Carolina 28209-3734 —
Pfizer Investigational Site Salisbury North Carolina 28144 —
Pfizer Investigational Site Cincinnati Ohio 45219 —
Pfizer Investigational Site Cincinnati Ohio 45227 —
Pfizer Investigational Site Columbus Ohio 43213 —
Pfizer Investigational Site Dayton Ohio 45408 —
Pfizer Investigational Site Toledo Ohio 43623 —
Pfizer Investigational Site Bend Oregon 97701 —
Pfizer Investigational Site Eugene Oregon 97401 —
Pfizer Investigational Site Medford Oregon 97504 —
Pfizer Investigational Site Portland Oregon 97219 —
Pfizer Investigational Site Altoona Pennsylvania 16602 —
Pfizer Investigational Site Bethlehem Pennsylvania 18015 —
Pfizer Investigational Site Bridgeville Pennsylvania 15017 —
Pfizer Investigational Site Duncansville Pennsylvania 16635 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15216 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15241 —
Pfizer Investigational Site Pittsburgh Pennsylvania 15243 —
Pfizer Investigational Site West Reading Pennsylvania 19611-1124 —
Pfizer Investigational Site Cumberland Rhode Island 02864 —
Pfizer Investigational Site Bristol Tennessee 37620 —
Pfizer Investigational Site Nashville Tennessee 37203 —
Pfizer Investigational Site Austin Texas 78758 —
Pfizer Investigational Site Austin Texas 78759 —
Pfizer Investigational Site Beaumont Texas 77701 —
Pfizer Investigational Site Bryan Texas 77802 —
Pfizer Investigational Site Dallas Texas 75231 —
Pfizer Investigational Site DeSoto Texas 75115 —
Pfizer Investigational Site Lake Jackson Texas 77566 —
Pfizer Investigational Site Nassau Bay Texas 77058 —
Pfizer Investigational Site San Antonio Texas 78229 —
Pfizer Investigational Site Ogden Utah 84405 —
Pfizer Investigational Site Salt Lake City Utah 84107 —
Pfizer Investigational Site Arlington Virginia 22205-3617 —
Pfizer Investigational Site Charlottesville Virginia 22911 —
Pfizer Investigational Site Virginia Beach Virginia 23455 —
Pfizer Investigational Site Kirkland Washington 98033 —
Pfizer Investigational Site Spokane Washington 99216 —
Pfizer Investigational Site Milwaukee Wisconsin 53209-0966 —
Pfizer Investigational Site Oregon Wisconsin 53575 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00754221, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 17, 2019 · Synced Nov 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00754221 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →